More and more countries are reaching the “threshold” of resistance to the most commonly-used HIV drugs which could “undermine global progress in treating and preventing HIV”, according to the World Health Organisation (WHO).Read More
The much-anticipated antiretroviral (ARV) dolutegravir will be introduced as the first-line treatment for the HIV infected in South Africa as early as April, Health Department deputy director-general Dr Yogan Pillay said at the 9th International Aids Society (IAS) conference on HIV Science in Paris this week.Read More
Alarming research has found that two-thirds of women of child-bearing age have had an unplanned pregnancy in the last five years.Read More
The manager of a South African anti-human trafficking helpline made two claims about the number of slaves and 'child prostitutes' in South Africa. Africa Check investigated these startling claims.Read More
Pharmacies are no longer prohibited from selling HIV self-testing kits.Read More
A study to evaluate a new antiretroviral drug combination for the treatment of HIV was launched yesterday by the Wits Reproductive Health and HIV Institute (RHI) together with its partners.Read More
A pill that protects against HIV has been approved for use in South Africa. Truvada, which contains two antiretrovirals, offers more than 90% protection against HIV if taken every day. Professor Francois Venter, Deputy Director of the Wits Reproductive Health and HIV Institute, welcomes the Medicines Control Council’s approval of the drug, saying: “There are no magic bullets in HIV prevention but we desperately need new and better options.Read More
The prevention of HIV from mothers to children has been the most successful HIV prevention programme in South Africa and across the globe. However Dr Lee Fairlie, Technical Head from Wits RHI, believes that certain areas need attention to reduce the burden of paediatric HIV.Read More
Two years ago women were found to have lied in a clinical trial in South Africa for a new HIV drug. The VOICE trial was unsuccessful due to low adherence. When the trial was completed it was revealed many women involved had not been honest about their adherence to the drug regime they had signed up to take. Jonathan Stadler, Technical Head, from Wits RHI explains his findings in this article.Read More
Wits RHI would like to congratulate Shobna Sawry our Programme Manager in Paediatric Research for receiving the LÓreal Unesco Regional Sub-Saharan Fellowship. This funding from global cosmetics giant L’Oreal will be used towards furthering her HIV/Aids research in paediatrics.
702’s Azania Mosaka spoke to her about her respective research subject and her vision for the role of science in eradicating the spread of HIV.